Cochrane COVID-19 Study Register
AboutHelp
Back to Search Results
NCT04347980

Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (8)
  2. Male and Female
  3. Acute Respiratory Distress Syndrome
  4. COVID-19
  5. Adult
  6. Aged (65+)
  1. Intervention (2)
  2. Dexamethasone
  3. Hydroxychloroquine
  1. Comparison (1)
  2. Hydroxychloroquine
  1. Outcome (9)
  2. Bacteremia
  3. Nosocomial Pneumonia
  4. Death
  5. Tracheostomy Tube
  6. Intensive Care
  7. Prone Positioning
  8. Mechanical ventilation
  9. Extracorporeal Membrane Oxygenation

Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome

NCT04347980
First Published (first received 2020)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT04347980)
Trial registry record
No Results
Single blind randomized clinical trial designed to evaluate the efficacy of the combination of hydroxychloroquine and dexamethasone as treatment for severe Acute Respiratory Distress Syndrome (ARDS) related to coronavirus disease 19 (COVID-19). We hypothesize that dexamethasone (20 mg for 5 days followed by 10 mg for 5 days) combined with 600 mg per day dose of hydroxychloroquine for 10 days will reduce the 28-day mortality compared to hydroxychloroquine alone in patients with severe ARDS related COVID-19